Candriam SCA’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.85M | Buy |
+278,888
| New | +$7.6M | 0.05% | 299 |
|
|
2024
Q3 | – | Sell |
-317,509
| Closed | -$11.8M | – | 690 |
|
|
2024
Q2 | $11.8M | Hold |
317,509
| – | – | 0.07% | 235 |
|
|
2024
Q1 | $13.3M | Hold |
317,509
| – | – | 0.09% | 221 |
|
|
2023
Q4 | $12.6M | Sell |
317,509
-5,000
| -2% | -$147K | 0.09% | 224 |
|
|
2023
Q3 | $8.88M | Sell |
322,509
-228,000
| -41% | -$7.15M | 0.06% | 239 |
|
|
2023
Q2 | $18.7M | Sell |
550,509
-45,000
| -8% | -$1.52M | 0.14% | 170 |
|
|
2023
Q1 | $19.7M | Buy |
595,509
+107,000
| +22% | +$4.62M | 0.14% | 170 |
|
|
2022
Q4 | $21.8M | Buy |
488,509
+70,000
| +17% | +$2.5M | 0.15% | 159 |
|
|
2022
Q3 | $11.8M | Buy |
418,509
+127,715
| +44% | +$3.92M | 0.08% | 233 |
|
|
2022
Q2 | $7.84M | Buy |
290,794
+13,313
| +5% | +$387K | 0.06% | 263 |
|
|
2022
Q1 | $9.45M | Sell |
277,481
-109,740
| -28% | -$3.51M | 0.06% | 265 |
|
|
2021
Q4 | $15M | Buy |
387,221
+206,999
| +115% | +$9.02M | 0.1% | 209 |
|
|
2021
Q3 | $9.73M | Sell |
180,222
-219,463
| -55% | -$10.3M | 0.07% | 277 |
|
|
2021
Q2 | $13.4M | Buy |
399,685
+55,546
| +16% | +$1.52M | 0.09% | 243 |
|
|
2021
Q1 | $5.79M | Hold |
344,139
| – | – | 0.05% | 348 |
|
|
2020
Q4 | $6.03M | Buy |
+344,139
| New | +$6.19M | 0.05% | 357 |
|
|
2016
Q1 | – | Sell |
-5,733
| Closed | -$1.35M | – | 638 |
|
|
2015
Q4 | $1.35M | Sell |
5,733
-3,034
| -35% | -$661K | 0.04% | 350 |
|
|
2015
Q3 | $1.39M | Sell |
8,767
-2,233
| -20% | -$632K | 0.03% | 390 |
|
|
2015
Q2 | $4.16M | Sell |
11,000
-667
| -6% | -$265K | 0.09% | 268 |
|
|
2015
Q1 | $4.88M | Buy |
11,667
+2,334
| +25% | +$835K | 0.1% | 258 |
|
|
2014
Q4 | $2.56M | Buy |
+9,333
| New | +$2.32M | 0.05% | 326 |
|
Other funds holding CLDX
KCM
VCM
CC
EP